Consensus nomenclature for CD 8 T cell phenotypes in cancer

Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+ T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+ T cells in cancer.

[1]  C. Coopersmith,et al.  Phenotypic T Cell Exhaustion in a Murine Model of Bacterial Infection in the Setting of Pre-Existing Malignancy , 2014, PloS one.

[2]  D. Douek,et al.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. , 2014, The Journal of clinical investigation.

[3]  M. Borner,et al.  CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival , 2014, Journal of Translational Medicine.

[4]  A. Strasser,et al.  Fas ligand–mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas , 2014, Nature Medicine.

[5]  Daniel E. Speiser,et al.  Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells , 2013, Front. Immunol..

[6]  Hong Wang,et al.  PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. , 2013, Cancer research.

[7]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[8]  C. Harris,et al.  p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. , 2013, The Journal of clinical investigation.

[9]  Jianhua Huang,et al.  Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer , 2013, Oncoimmunology.

[10]  F. Sallusto,et al.  The who's who of T‐cell differentiation: Human memory T‐cell subsets , 2013, European journal of immunology.

[11]  Jae Hyun Kim,et al.  Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer , 2013, British Journal of Cancer.

[12]  H. Pircher,et al.  Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype , 2013, Cancer Immunology, Immunotherapy.

[13]  C. Sautès-Fridman,et al.  Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin , 2013, Clinical Cancer Research.

[14]  A. Legat,et al.  T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion , 2013, Nature Immunology.

[15]  B. Lippitz,et al.  Cytokine patterns in patients with cancer: a systematic review. , 2013, The Lancet. Oncology.

[16]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[17]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[18]  T. Waldmann,et al.  Superior T memory stem cell persistence supports long-lived T cell memory. , 2013, The Journal of clinical investigation.

[19]  N. Restifo,et al.  Moving T memory stem cells to the clinic. , 2013, Blood.

[20]  S. Bicciato,et al.  IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. , 2013, Blood.

[21]  F. Ghiringhelli,et al.  Controversies on the role of Th17 in cancer: a TGF-β-dependent immunosuppressive activity? , 2012, Trends in molecular medicine.

[22]  C. Melief,et al.  Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors , 2012, The Journal of Immunology.

[23]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[24]  J. Economou,et al.  Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs , 2012, Molecular Cancer Therapeutics.

[25]  T. Niki,et al.  IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[26]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[27]  Ornella Pagliano,et al.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.

[28]  C. Fegan,et al.  Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression , 2011, Clinical Cancer Research.

[29]  E. Yang,et al.  The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets , 2011, Nature Immunology.

[30]  F. Marincola,et al.  Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits CD8+ T cell memory formation , 2011, Nature Immunology.

[31]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[32]  S. Loi,et al.  Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. , 2011, Cancer research.

[33]  C. Coutant,et al.  In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival , 2011, The Journal of pathology.

[34]  F. Végran,et al.  Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. , 2011, Current molecular medicine.

[35]  Pedro Romero,et al.  Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. , 2011, The Journal of clinical investigation.

[36]  E John Wherry,et al.  T cell exhaustion , 2011 .

[37]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[39]  J. Campisi,et al.  Four faces of cellular senescence , 2011, The Journal of cell biology.

[40]  G. Splitter,et al.  Antigen specific killing assay using CFSE labeled target cells. , 2010, Journal of visualized experiments : JoVE.

[41]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[42]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[43]  H. Shirato,et al.  Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. , 2010, Cancer research.

[44]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[45]  F. Johnson,et al.  Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation , 2009, Clinical Cancer Research.

[46]  R. Weichselbaum,et al.  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. , 2009, Blood.

[47]  S. J. Griffiths,et al.  KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. , 2009, Blood.

[48]  J. Kirkwood,et al.  PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients1 , 2009, The Journal of Immunology.

[49]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[50]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[51]  Rong-Fu Wang.  CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. , 2008, Human immunology.

[52]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[53]  Philippe Bousso,et al.  Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. , 2008, The Journal of clinical investigation.

[54]  M. Karin,et al.  The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. , 2008, Trends in molecular medicine.

[55]  A. Chapoval,et al.  Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. , 2008, Cancer research.

[56]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[57]  Sebastian Amigorena,et al.  In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor , 2007, The Journal of experimental medicine.

[58]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[59]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[60]  J. Dausset,et al.  Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[62]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Curiel,et al.  Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. , 2005, Cancer research.

[64]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[65]  H. Schreiber,et al.  Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.

[66]  Hao Shen,et al.  Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin , 2003, Science.

[67]  Mario Roederer,et al.  Ex vivo identification, isolation and analysis of tumor-cytolytic T cells , 2003, Nature Medicine.

[68]  M. H. Ryan,et al.  The Fas/Fas Ligand Pathway Is Important for Optimal Tumor Regression in a Mouse Model of CTL Adoptive Immunotherapy of Experimental CMS4 Lung Metastases , 2003, The Journal of Immunology.

[69]  H. Pircher,et al.  A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells , 2003 .

[70]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[71]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[72]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[73]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[74]  D. Voehringer,et al.  Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). , 2002, Blood.

[75]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[76]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[77]  R. Bleackley,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[78]  T. Sayers,et al.  Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin1 , 2002, The Journal of Immunology.

[79]  R. Vile.  Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[80]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[81]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[82]  M. Roederer,et al.  11-color, 13-parameter flow cytometry: Identification of human naive T cells by phenotype, function, and T-cell receptor diversity , 2001, Nature Medicine.

[83]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[84]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[85]  Wever,et al.  The CD8+ granzyme B+ T‐cell subset in peripheral blood from healthy individuals contains activated and apoptosis‐prone cells , 1998, Immunology.

[86]  W. Catalona,et al.  T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. , 1993, The Journal of urology.

[87]  G. Griffiths,et al.  Granzymes A and B are targeted to the lytic granules of lymphocytes by the mannose-6-phosphate receptor , 1993, The Journal of cell biology.

[88]  N. Sato,et al.  Actions of TNF and IFN-gamma on angiogenesis in vitro. , 1990, The Journal of investigative dermatology.

[89]  N. Sato,et al.  Actions of TNF and INF-γ on Angiogenesis In Vitro , 1990 .

[90]  F. Belardelli,et al.  Anti‐tumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases , 1990, International journal of cancer.

[91]  J. Tschopp,et al.  A family of serine esterases in lytic granules of cytolytic T lymphocytes , 1987, Cell.

[92]  C. Verret,et al.  Serine esterase in cytolytic T lymphocytes , 1986, Nature.

[93]  E. Nakayama,et al.  Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection , 1985, The Journal of experimental medicine.

[94]  E. Podack,et al.  Cytolytic T cell granules. Isolation, structural, biochemical, and functional characterization , 1984, The Journal of experimental medicine.

[95]  C. Uyttenhove,et al.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression , 1983, The Journal of experimental medicine.

[96]  B. Chapuis,et al.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. , 1968, Immunology.

[97]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.

[98]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[99]  H. Pircher,et al.  A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.

[100]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[101]  J. Harty,et al.  CD8+ T cell effector mechanisms in resistance to infection. , 2000, Annual review of immunology.